Moreover, MYH9 promotes tumor progression by modulating the immune microenvironment, so reduced MYH9 level by ITE treatment potentially offers immune-promoting benefit in addition to its invasion-inhibiting effects [30]. Here, MYH9 is linked to neoplasm.